Patent intelligence · US
US 8858925
Pegylated fibrinogen precursor molecule
Pegylated fibrinogen precursor molecule
Patent details — US 8858925
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 14, 2014
- Expiration
- Oct 9, 2034
- Applicant
- REGENTIS BIOMATERIALS LTD.
- Claims
- 9
- CPC classes
- A61K, A61K38/363, A61K38/39, A61K38/45
Quick answer
US 8858925 (Pegylated fibrinogen precursor molecule) is held by REGENTIS BIOMATERIALS LTD.. Status: granted. Granted Oct 14, 2014. Expires Oct 9, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENTIS BIOMATERIALS LTD.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K38/363, A61K38/39, A61K38/45, A61K47/60, A61K47/6435
More from REGENTIS BIOMATERIALS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8858925?
US 8858925 (Pegylated fibrinogen precursor molecule) is held by REGENTIS BIOMATERIALS LTD.. Status: granted. Granted Oct 14, 2014. Expires Oct 9, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8858925?
REGENTIS BIOMATERIALS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8858925 expire?
Our index shows an expiration date of Oct 9, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.